feedback

Course Director

Roy F. Chemaly, MD, MPH, FIDSA, FACP
Roy F. Chemaly, MD, MPH, FIDSA, FACP

The University of Texas MD Anderson Cancer Center
Houston, Texas

Faculty

Genovefa Papanicolaou
Genovefa Papanicolaou, MD

Memorial Sloan Kettering Cancer Center
Weill Cornell Medicine, Medical College
New York, New York

Accredited by

The Medical College of Wisconsin

Activity Details

Credit Types:CME
Credit Amount:1.0 Credits
Release Date:2020-Mar-20
Expiration Date:2021-Mar-19
Estimated Time for Completion:60 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

Cytomegalovirus (CMV) is a leading opportunistic infection in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HCT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to the emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. After many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. Indeed, letermovir was recently approved for CMV prophylaxis in allogeneic HCT recipients, and data suggest that maribavir has the potential to address the unmet need of treating relapsed or resistant CMV infections. In this activity, based on a live symposium, experts offer insight into managing CMV in HCT recipients in a new era of antiviral therapy. Foundational guidance is combined with a discussion of real cases. Hear about best practices in preventing CMV infection in patients undergoing HCT, as well as the potential role of novel antiviral therapies in resistant/refractory CMV.

Upon completion of this activity, participants should be better able to:
  • Discuss the burden of cytomegalovirus (CMV) infection among hematopoietic stem cell transplant (HCT) recipients
  • Assess the latest clinical trial data regarding novel strategies to prevent and treat CMV infection in the HCT setting
  • Employ strategies to prevent and treat CMV infection in individual HCT recipients, considering current evidence, expert recommendations, and clinical trial enrollment for appropriate patients

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, BMT specialists, BMT nurse specialists, and other clinicians involved in the management of transplant recipients at risk for CMV.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: March 20, 2020 - March 19, 2021
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Co-Chair and Presenter

Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Infection Control Section
Director, Clinical Virology Research
Department of Infectious Disease, Infection Control and Employee Health
The University of Texas MD Anderson Cancer Center
Houston, Texas

Roy F. Chemaly, MD, MPH, FIDSA, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Ansun BioPharma; Chimerix; Clinigen Group plc.; Janssen Pharmaceuticals, Inc.; Kyorin Pharmaceutical Co., Ltd; Merck & Co., Inc.; Oxford Immunotec USA, Inc.; Paratek Pharmaceuticals, Inc.; Pulmotect, Inc.; ReViral Ltd; Shire; and Xenex Laboratories.
Grant/Research Support from Ansun BioPharma; Chimerix; Eurofins Viracor, Inc.; Gilead; Merck & Co., Inc.; Karius, Inc.; Oxford Immunotec USA, Inc.; Pulmotect, Inc.; and Xenex Laboratories.

Co-Chair and Presenter

Genovefa Papanicolaou, MD, FIDSA
Director, Clinical Trials, Infectious Disease Specialist
Memorial Sloan Kettering Cancer Center
Professor, Weill Cornell Medical College
Cornell University
New York, New York

Genovefa Papanicolaou, MD, FIDSA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for ADMA Biologics, Inc.; Astellas Pharma US, Inc.; Merck & Co., Inc.; Nabriva Therapeutics plc; Octapharma; Shionogi Inc.; and Siemens.
Grant/Research Support from Astellas Pharma US, Inc.; Chimerix; and Merck & Co., Inc.
Speakers Bureau participant with Amplyx and Merck & Co., Inc.
Data Safety Monitoring Board for Amplyx and Merck & Co., Inc.

Medical Director

Kathryn B. Charalambous, PhD
PVI, PeerView Institute for Medical Education

Kathryn B. Charalambous, PhD, has no financial interests/relationships or affiliations in relation to this activity.

The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Providership, Credit, and Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.

The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

Providership


This CME activity is jointly provided by The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education.

Support

This educational activity is supported by independent medical educational grants from Merck & Co., Inc. and Shire.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and The Medical College of Wisconsin are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and The Medical College of Wisconsin.

Copyright © 2000-2020, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.